Literature DB >> 19742203

Hypertensive crisis and cheese.

T S Sathyanarayana Rao, Vikram K Yeragani.   

Abstract

Entities:  

Year:  2009        PMID: 19742203      PMCID: PMC2738414          DOI: 10.4103/0019-5545.44910

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


× No keyword cloud information.
[Editor's Note: This article is one of the new Sections we are adding to encourage the psychiatric trainees and other faculty members to critically examine some of the interesting discoveries and phenomena that relate to Psychiatry directly or indirectly. Many great discoveries have been rather serendipitous experiences in Medicine, in general. We would like to begin this with a very significant side-effect of monoamine oxidase inhibitors (MAOI), the “cheese reaction”. These drugs came into psychiatric practice since the euphoriant effects of ipronizid were uncovered during treatment of tuberculosis.] “It is not enough to know that cheese is a bad article of food for cheese does not harm all people equally. If it had been harmful to the human constitution in general, everyone would have suffered. Now whoever knows these facts will not suffer” The tyramine connection was discovered by a British pharmacist whose wife was taking an monoamine oxidase inhibitors (MAOI). He noticed that every time they had a meal with cheese, she would get a severe headache. Cheese, especially aged cheese, contains substantial amount of tyramine. For this reason, persons taking MAOI antidepressants are cautioned to avoid foods that are rich in tyramine so that the hypertensive crises can be avoided. However, the road to understanding the neurochemical mechanism of this phenomenon was rather a long and tortuous one. Hypertensive crises due to phenelzine were reported by Dally and Tailor in 1962 but these episodes are commoner with tranylcypromine. Barry Blackwell systematically described these side-effects in 12 patients and 10 of these were women. Eleven patients were receiving tranylcypromine and one, phenelzine. In majority that had the reaction, cooked or raw cheese was the precipitating agent. Increases in blood pressure (BP) ranged from 160/90 to 220/115 mm Hg. The onset of the episode was usually one to two hours after the food intake. Headache was the main symptom associated with heart pounding and palpitations and the complications included subarachnoid hemorrhage, hemiplegia, intracranial hemorrhage, cardiac arrhythmias, cardiac failure, pulmonary edema, and death. Dally noted the striking similarity of this phenomenon to symptoms of pheochromocytoma and suggested that the release of pressor amine locally or systemically might be responsible for this effect. The increase in tissue concentrations of epinephrine and norepinephrine supports this view. Cheese contains both tyramine and histamine. Tyramine was the first known substrate of monoamine oxidase (MAO). Tyramine was first isolated from cheese and later named after the Greek (tyros) for cheese. Tyramine oxidase occurs in high concentrations in intestinal mucosa. The pressor amines in the gut form as a result of bacterial decarboxylation of amino acids. In this context, it should be noted that the adverse effects resulting from the absorption of some of these amines was described by Metchinkoff as early as in 1905. Blackwell and co-workers have done substantial amount of work on this issue along with many other great researchers. During ripening of cheeses, the casein is broken down to form peptides and free aminoacids. In 1965[1] in their seminal article, Blackwell and co-workers have shown that tyramine in cheese is related to the hypertensive crises after MAO inhibition. They have determined the tyramine content of 14 different cheddar cheeses and several Wensleydale, Cheshire and Caerphilly cheeses. The reactions were variable as the amount of tyramine in the 14 cheddar cheeses varied from 72 to 953 mcg per gram of cheese. An oral dose of even 6 mg of tyramine can increase BP. However, the dangerous dose for different people varies significantly from anywhere about 25 mg of tyramine. Thus, Blackwell and co-workers[1-3] were the first to systematically quantify the amines in cheese. In addition to tyramine, hypertensive responses can also be associated particularly with over-the-counter sympathomimetic drugs such as ephedrine, pseudoephedrine and phenylpropanolamine, which are present in several decongestants and cough medicines. Hypertension may also occur when MAOIs are combined with L-dopa, methylphenidate, dextroamphetamine, reserpine, guanethidine, or tetrabenazine. Deprenyl, a specific MAO-B inhibitor at low doses (10 mg/day), can be administered safely with dietary tyramine, L-dopa, or L-dopa plus a decarboxylase inhibitor. For clinicians, the differentiation of true hypertensive crises from rebound headaches caused by MAOI-induced postural hypotension is important to treat the hypertensive crises early. Agents normally used to lower blood pressure during a hypertensive crisis include nifedipine, a calcium channel blocker or phentolamine, an alpha adrenergic blocker.
  3 in total

1.  INTERACTION BETWEEN CHEESE AND MONOAMINE-OXIDASE INHIBITORS IN RATS AND CATS.

Authors:  B BLACKWELL; E MARLEY
Journal:  Lancet       Date:  1964-03-07       Impact factor: 79.321

2.  HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS.

Authors:  B BLACKWELL
Journal:  Lancet       Date:  1963-10-26       Impact factor: 79.321

3.  TYRAMINE IN CHEESE RELATED TO HYPERTENSIVE CRISES AFTER MONOAMINE-OXIDASE INHIBITION.

Authors:  B BLACKWELL; L A MABBITT
Journal:  Lancet       Date:  1965-05-01       Impact factor: 79.321

  3 in total
  9 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

Review 2.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

Review 3.  Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.

Authors:  Narayan D Chaurasiya; Francisco Leon; Ilias Muhammad; Babu L Tekwani
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

Review 4.  Treatment strategies for clozapine-induced hypotension: a systematic review.

Authors:  Timothy David Tanzer; Thomas Brouard; Samuel Dal Pra; Nicola Warren; Michael Barras; Steve Kisely; Emily Brooks; Dan Siskind
Journal:  Ther Adv Psychopharmacol       Date:  2022-05-24

5.  Role of cationic drug-sensitive transport systems at the blood-cerebrospinal fluid barrier in para-tyramine elimination from rat brain.

Authors:  Shin-Ichi Akanuma; Yuhei Yamazaki; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Fluids Barriers CNS       Date:  2018-01-08

6.  Food-drug interactions: Knowledge among pharmacists in Jordan.

Authors:  Mohammed Zawiah; Al-Motassem Yousef; Amer Hayat Khan; Fahmi Y Al-Ashwal; Amal Matar; Batool ALKhawaldeh; Rand Nassar; Rami Abduljabbar; Abdullah Abdulmajid Abdo Ahmed
Journal:  PLoS One       Date:  2020-06-17       Impact factor: 3.240

Review 7.  Technological Factors Affecting Biogenic Amine Content in Foods: A Review.

Authors:  Fausto Gardini; Yesim Özogul; Giovanna Suzzi; Giulia Tabanelli; Fatih Özogul
Journal:  Front Microbiol       Date:  2016-08-12       Impact factor: 5.640

8.  Inter-individual and inter-regional variations in enteric drug metabolizing enzyme activities: Results with cryopreserved human intestinal mucosal epithelia (CHIM) from the small intestines of 14 donors.

Authors:  Albert P Li; Ming-Chih D Ho; Novera Alam; Walter Mitchell; Susan Wong; Zhengyin Yan; Jane R Kenny; Cornelis E C A Hop
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 9.  The trace aminergic system: a gender-sensitive therapeutic target for IBS?

Authors:  Lesha Pretorius; Carine Smith
Journal:  J Biomed Sci       Date:  2020-09-28       Impact factor: 8.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.